{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T18:45:05Z","timestamp":1785869105760,"version":"3.56.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.ygyno.2019.03.260","type":"journal-article","created":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T08:26:55Z","timestamp":1554798415000},"page":"535-540","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer"],"prefix":"10.1016","volume":"153","author":[{"given":"Sandro","family":"Pignata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenica","family":"Lorusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Ornella","family":"Nicoletto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Lauria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Mosconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosimo","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Omarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierosandro","family":"Tagliaferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8036-9323","authenticated-orcid":false,"given":"Gabriella","family":"Ferrandina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"Cinieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Savarese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Valabrega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Pisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanda","family":"Salutari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Raspagliesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Kopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina Chiara","family":"Cecere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Amadio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppa","family":"Maltese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilena","family":"Di Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Greggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Signoriello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"Daniele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Losito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Normanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9738-0526","authenticated-orcid":false,"given":"Francesco","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9519-4757","authenticated-orcid":false,"given":"Maria Carmela","family":"Piccirillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2019.03.260_bb0005","doi-asserted-by":"crossref","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer. 2015;136:E359\u201386.","DOI":"10.1002\/ijc.29210"},{"key":"10.1016\/j.ygyno.2019.03.260_bb0010","unstructured":"Fuchs I, Vorsteher N, Buhler H, Evers K, Sehouli J, Schaller G, et al. The prognostic significance of human epidermal growth factor receptor correlations in squamous cell cervical carcinoma. Anticancer Res.. 2007;27:959\u201363."},{"key":"10.1016\/j.ygyno.2019.03.260_bb0015","doi-asserted-by":"crossref","unstructured":"Bellone S, Frera G, Landolfi G, Romani C, Bandiera E, Tognon G, et al. Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent\/metastatic disease. Gynecol. Oncol.. 2007;106:513\u201320.","DOI":"10.1016\/j.ygyno.2007.04.028"},{"key":"10.1016\/j.ygyno.2019.03.260_bb0020","doi-asserted-by":"crossref","unstructured":"Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med.. 2007;357:2040\u20138.","DOI":"10.1056\/NEJMoa071834"},{"key":"10.1016\/j.ygyno.2019.03.260_bb0025","doi-asserted-by":"crossref","unstructured":"Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.. 2011;29:2011\u20139.","DOI":"10.1200\/JCO.2010.33.5091"},{"key":"10.1016\/j.ygyno.2019.03.260_bb0030","doi-asserted-by":"crossref","unstructured":"Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol.. 2014;15:1065\u201375.","DOI":"10.1016\/S1470-2045(14)70330-4"},{"key":"10.1016\/j.ygyno.2019.03.260_bb0035","doi-asserted-by":"crossref","unstructured":"Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med.. 2008;359:1116\u201327.","DOI":"10.1056\/NEJMoa0802656"},{"key":"10.1016\/j.ygyno.2019.03.260_bb0040","doi-asserted-by":"crossref","unstructured":"Thienelt CD, Bunn PA, Jr., Hanna N, Rosenberg A, Needle MN, Long ME, et al. Multicenter phase I\/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.. 2005;23:8786\u201393.","DOI":"10.1200\/JCO.2005.03.1997"},{"key":"10.1016\/j.ygyno.2019.03.260_bb0045","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1081\/CNV-200029062","article-title":"Paclitaxel and carboplatin for recurrent or persistent cancer of the cervix","volume":"22","author":"Sit","year":"2004","journal-title":"Cancer Investig."},{"key":"10.1016\/j.ygyno.2019.03.260_bb0050","doi-asserted-by":"crossref","unstructured":"Kitagawa R, Katsumata N, Shibata T, Kamura T, Kasamatsu T, Nakanishi T, et al. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.. 2015;33:2129\u201335.","DOI":"10.1200\/JCO.2014.58.4391"},{"key":"10.1016\/j.ygyno.2019.03.260_bb0055","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ygyno.2005.03.037","article-title":"Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma: the British Columbia Cancer Agency experience","volume":"98","author":"Tinker","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.03.260_bb0060","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1200\/JCO.2006.09.3781","article-title":"Management of metastatic cervical cancer: review of the literature","volume":"25","author":"Long","year":"2007","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.03.260_bb0065","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1200\/JCO.2001.19.1.265","article-title":"Clinical trial designs for cytostatic agents: are new approaches needed?","volume":"19","author":"Korn","year":"2001","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.03.260_bb0070","doi-asserted-by":"crossref","first-page":"7199","DOI":"10.1200\/JCO.2005.01.149","article-title":"Design issues of randomized phase II trials and a proposal for phase II screening trials","volume":"23","author":"Rubinstein","year":"2005","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.03.260_bb0075","doi-asserted-by":"crossref","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst.. 2000;92:205\u201316.","DOI":"10.1093\/jnci\/92.3.205"},{"key":"10.1016\/j.ygyno.2019.03.260_bb0080","first-page":"509","article-title":"A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group","volume":"18","author":"Lacouture","year":"2010","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.ygyno.2019.03.260_bb0085","doi-asserted-by":"crossref","unstructured":"Ojesina AI, Lichtenstein L, Freeman SS, Pedamallu CS, Imaz-Rosshandler I, Pugh TJ, et al. Landscape of genomic alterations in cervical carcinomas. Nature. 2014;506:371\u20135.","DOI":"10.1038\/nature12881"},{"key":"10.1016\/j.ygyno.2019.03.260_bb0090","doi-asserted-by":"crossref","unstructured":"Santin AD, Sill MW, McMeekin DS, Leitao MM, Jr., Brown J, Sutton GP, et al. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol. Oncol.. 2011;122:495\u2013500.","DOI":"10.1016\/j.ygyno.2011.05.040"},{"key":"10.1016\/j.ygyno.2019.03.260_bb0095","doi-asserted-by":"crossref","unstructured":"Kurtz JE, Hardy-Bessard AC, Deslandres M, Lavau-Denes S, Largillier R, Roemer-Becuwe C, et al. Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: a phase II GINECO trial. Gynecol. Oncol.. 2009;113:16\u201320.","DOI":"10.1016\/j.ygyno.2008.12.040"},{"key":"10.1016\/j.ygyno.2019.03.260_bb0100","doi-asserted-by":"crossref","unstructured":"Farley J, Sill MW, Birrer M, Walker J, Schilder RJ, Thigpen JT, et al. Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study. Gynecol. Oncol.. 2011;121:303\u20138.","DOI":"10.1016\/j.ygyno.2011.01.030"},{"key":"10.1016\/j.ygyno.2019.03.260_bb0105","doi-asserted-by":"crossref","unstructured":"Braig F, Voigtlaender M, Schieferdecker A, Busch CJ, Laban S, Grob T, et al. Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma. Oncotarget. 2016.","DOI":"10.18632\/oncotarget.8943"},{"key":"10.1016\/j.ygyno.2019.03.260_bb0110","doi-asserted-by":"crossref","unstructured":"Khambata-Ford S, Harbison CT, Hart LL, Awad M, Xu LA, Horak CE, et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane\/carboplatin in advanced non-small-cell lung cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.. 2010;28:918\u201327.","DOI":"10.1200\/JCO.2009.25.2890"},{"key":"10.1016\/j.ygyno.2019.03.260_bb0115","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1158\/1078-0432.CCR-14-2368","article-title":"PIK3CA pathway mutations predictive of poor response following standard radiochemotherapy +\/\u2212 Cetuximab in cervical cancer patients","volume":"21","author":"de la Rochefordiere","year":"2015","journal-title":"Clin. Cancer Res."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819304950?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819304950?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:42:32Z","timestamp":1758771752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825819304950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0090825819304950"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.03.260","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.03.260","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}